These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 35753279)
1. Differences in buprenorphine treatment quality across physician provider specialties. Levin JS; Landis RK; Sorbero M; Dick AW; Saloner B; Stein BD Drug Alcohol Depend; 2022 Aug; 237():109510. PubMed ID: 35753279 [TBL] [Abstract][Full Text] [Related]
2. Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies. Landis RK; Opper I; Saloner B; Gordon AJ; Leslie DL; Sorbero M; Stein BD Drug Alcohol Depend; 2022 Dec; 241():109669. PubMed ID: 36332589 [TBL] [Abstract][Full Text] [Related]
3. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints. Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761 [TBL] [Abstract][Full Text] [Related]
4. Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders. Clark B; Kai M; Dix R; White J; Rozenfeld Y; Levy S; Engstrom K JAMA Netw Open; 2019 Oct; 2(10):e1913818. PubMed ID: 31642929 [TBL] [Abstract][Full Text] [Related]
5. Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialties. Lin LA; Lofwall MR; Walsh SL; Knudsen HK Addict Behav; 2019 Jun; 93():72-77. PubMed ID: 30690416 [TBL] [Abstract][Full Text] [Related]
6. Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine. Landis RK; Levin JS; Saloner B; Gordon AJ; Dick AW; Sherry TB; Leslie DL; Sorbero M; Stein BD Subst Abus; 2022 Dec; 43(1):1057-1071. PubMed ID: 35442178 [No Abstract] [Full Text] [Related]
7. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States? Rhee TG; Rosenheck RA Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111 [TBL] [Abstract][Full Text] [Related]
8. Characteristics and current clinical practices of opioid treatment programs in the United States. Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836 [TBL] [Abstract][Full Text] [Related]
9. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees. Wen H; Hockenberry JM; Pollack HA JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185 [TBL] [Abstract][Full Text] [Related]
10. Composition of buprenorphine prescribing networks in Medicaid and association with quality of care. Zhu JM; Charlesworth CJ; Stein BD; Drake C; Polsky D; Korthuis PT; McConnell KJ J Subst Use Addict Treat; 2024 Aug; 163():209363. PubMed ID: 38641055 [TBL] [Abstract][Full Text] [Related]
11. Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims. Xu KY; Gertner AK; Greenfield SF; Williams AR; Grucza RA Addict Sci Clin Pract; 2024 Mar; 19(1):17. PubMed ID: 38493109 [TBL] [Abstract][Full Text] [Related]
12. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States. Parish WJ; Mark TL; Zarkin GA; Weber E Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177 [TBL] [Abstract][Full Text] [Related]
13. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine. Du CX; Shi J; Tetrault JM; Madden LM; Barry DT Fam Pract; 2022 Mar; 39(2):234-240. PubMed ID: 34893825 [TBL] [Abstract][Full Text] [Related]
14. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Rosenblatt RA; Andrilla CH; Catlin M; Larson EH Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888 [TBL] [Abstract][Full Text] [Related]
15. National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018. Schuler MS; Saloner B; Gordon AJ; Dick AW; Stein BD Subst Abus; 2023 Jul; 44(3):154-163. PubMed ID: 37278310 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA; Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068 [TBL] [Abstract][Full Text] [Related]
17. A mixed methods study of HIV-related services in buprenorphine treatment. Knudsen HK; Cook J; Lofwall MR; Walsh SL; Studts JL; Havens JR Subst Abuse Treat Prev Policy; 2017 Aug; 12(1):37. PubMed ID: 28814313 [TBL] [Abstract][Full Text] [Related]
18. Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program. Gordon AJ; Lo-Ciganic WH; Cochran G; Gellad WF; Cathers T; Kelley D; Donohue JM J Addict Med; 2015; 9(6):470-7. PubMed ID: 26517324 [TBL] [Abstract][Full Text] [Related]
19. Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes. Schuman-Olivier Z; Hoeppner BB; Weiss RD; Borodovsky J; Shaffer HJ; Albanese MJ Drug Alcohol Depend; 2013 Oct; 132(3):580-6. PubMed ID: 23688843 [TBL] [Abstract][Full Text] [Related]